Till sidinnehåll
Kunskapsbank för cancervården Till cancercentrum.se


Aboudaram, A., Modesto, A., Chaltiel, L., Gomez-Roca, C., Boulinguez, S., Sibaud, V., . . . Meyer, N. (2017). Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination. Melanoma Res, 27(5), 485-491. doi:10.1097/cmr.0000000000000386

Agrawal, S., Kane, J. M., 3rd, Guadagnolo, B. A., Kraybill, W. G., & Ballo, M. T. (2009). The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer, 115(24), 5836-5844. doi:10.1002/cncr.24627

Ahmed, K. A., Stallworth, D. G., Kim, Y., Johnstone, P. A., Harrison, L. B., Caudell, J. J., . . . Gibney, G. T. (2016). Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Ann Oncol, 27(3), 434-441. doi:10.1093/annonc/mdv622

Altamura, D., Avramidis, M., & Menzies, S. W. (2008). Assessment of the optimal interval for and sensitivity of short-term sequential digital dermoscopy monitoring for the diagnosis of melanoma. Arch Dermatol, 144(4), 502-506. doi:10.1001/archderm.144.4.502

Amant, F., Vandenbroucke, T., Verheecke, M., Fumagalli, M., Halaska, M. J., Boere, I., . . . Van Calsteren, K. (2015). Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy. N Engl J Med, 373(19), 1824-1834. doi:10.1056/NEJMoa1508913

Amaria, R. N., Reddy, S. M., Tawbi, H. A., Davies, M. A., Ross, M. I., Glitza, I. C., . . . Wargo, J. A. (2018). Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med, 24(11), 1649-1654. doi:10.1038/s41591-018-0197-1

Amersi, F., & Morton, D. L. (2007). The role of sentinel lymph node biopsy in the management of melanoma. Adv Surg, 41, 241-256.

An, Y., Jiang, W., Kim, B. Y. S., Qian, J. M., Tang, C., Fang, P., . . . Li, J. (2017). Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiother Oncol, 125(1), 80-88. doi:10.1016/j.radonc.2017.08.009

Anderson, E. S., Postow, M. A., Wolchok, J. D., Young, R. J., Ballangrud, A., Chan, T. A., . . . Beal, K. (2017). Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment. J Immunother Cancer, 5(1), 76. doi:10.1186/s40425-017-0282-x

Andersson, T. M., Johansson, A. L., Fredriksson, I., & Lambe, M. (2015). Cancer during pregnancy and the postpartum period: A population-based study. Cancer, 121(12), 2072-2077. doi:10.1002/cncr.29325

Andtbacka, R. H., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., . . . Coffin, R. S. (2015). Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol, 33(25), 2780-2788. doi:10.1200/jco.2014.58.3377

Anker, C. J., Grossmann, K. F., Atkins, M. B., Suneja, G., Tarhini, A. A., & Kirkwood, J. M. (2016). Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG). Int J Radiat Oncol Biol Phys, 95(2), 632-646. doi:10.1016/j.ijrobp.2016.01.038

Armstrong, B. K., & Kricker, A. (2001). The epidemiology of UV induced skin cancer. J Photochem Photobiol B, 63(1-3), 8-18.

Ascierto, P. A., Bastholt, L., Hersey, P., Cinat, G., Eggermont, A. M., Hauschild, A., . . . Robert, C. (2015). Side effects and toxicities of targeted therapies in stage IV melanoma. Am J Ther, 22(1), 44-53. doi:10.1097/MJT.0b013e3182a39858

Ascierto, P. A., Del Vecchio, M., Mandalá, M., Gogas, H., Arance, A. M., Dalle, S., . . . Weber, J. (2020). Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol, 21(11), 1465-1477. doi:10.1016/s1470-2045(20)30494-0

Ascierto, P. A., Gogas, H. J., Grob, J. J., Algarra, S. M., Mohr, P., Hansson, J., & Hauschild, A. (2013). Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert review. Crit Rev Oncol Hematol, 85(2), 149-161. doi:10.1016/j.critrevonc.2012.07.004

Ascierto, P. A., McArthur, G. A., Dreno, B., Atkinson, V., Liszkay, G., Di Giacomo, A. M., . . . Larkin, J. (2016). Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol, 17(9), 1248-1260. doi:10.1016/s1470-2045(16)30122-x

Ascierto, P. e. a. Overall survival (OS) and safety results from a phase 3 trial of ipilimumab (IPI) at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma (MEL). ESMO meeting 2016
Retrieved from http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf

Balch, C. M., Gershenwald, J. E., Soong, S. J., Thompson, J. F., Atkins, M. B., Byrd, D. R., . . . Sondak, V. K. (2009). Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol, 27(36), 6199-6206. doi:10.1200/jco.2009.23.4799

Balch, C. M., Soong, S. J., Gershenwald, J. E., Thompson, J. F., Reintgen, D. S., Cascinelli, N., . . . Morabito, A. (2001). Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol, 19(16), 3622-3634.

Bang, A., Wilhite, T. J., Pike, L. R. G., Cagney, D. N., Aizer, A. A., Taylor, A., . . . Schoenfeld, J. D. (2017). Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. Int J Radiat Oncol Biol Phys, 98(2), 344-351. doi:10.1016/j.ijrobp.2017.02.003

Barnhill, R., Piepkorn, M., Busam, K. (2014). Pathology of Melanocytic Nevi and Melanoma (Vol. 3): Springer-Verlag Berlin and Heidelberg GmbH & Co. K.

Barnhill, R. L. (2006). The Spitzoid lesion: rethinking Spitz tumors, atypical variants, 'Spitzoid melanoma' and risk assessment. Mod Pathol, 19 Suppl 2, S21-33. doi:10.1038/modpathol.3800519

Bassino, S., Ribero, S., Miniotti, M., Picardi, A., Caliendo, V., Castelli, L., . . . Leombruni, P. (2017). Emotional distress and health-related quality of life among cutaneous melanoma follow-up outpatients: the role of self-perception of body image and surgical scarring. Eur J Dermatol, 27(4), 435-438. doi:10.1684/ejd.2017.3048

Bath-Hextall, F., Nalubega, S., & Evans, C. (2017). The needs and experiences of patients with skin cancer: a qualitative systematic review with metasynthesis. Br J Dermatol, 177(3), 666-687. doi:10.1111/bjd.15148

Bauer, J., & Garbe, C. (2003). Acquired melanocytic nevi as risk factor for melanoma development. A comprehensive review of epidemiological data. Pigment Cell Res, 16(3), 297-306.

Beesley, V. L., Smithers, B. M., Khosrotehrani, K., Khatun, M., O'Rourke, P., Hughes, M. C., . . . Green, A. C. (2015). Supportive care needs, anxiety, depression and quality of life amongst newly diagnosed patients with localised invasive cutaneous melanoma in Queensland, Australia. Psychooncology, 24(7), 763-770. doi:10.1002/pon.3718

Bergenmar, M., Hansson, J., & Brandberg, Y. (2002). Detection of nodular and superficial spreading melanoma with tumour thickness < or = 2.0 mm--an interview study. Eur J Cancer Prev, 11(1), 49-55.

Berger, M. F., Hodis, E., Heffernan, T. P., Deribe, Y. L., Lawrence, M. S., Protopopov, A., . . . Garraway, L. A. (2012). Melanoma genome sequencing reveals frequent PREX2 mutations. Nature, 485(7399), 502-506. doi:10.1038/nature11071

Bertino, G., Sersa, G., De Terlizzi, F., Occhini, A., Plaschke, C. C., Groselj, A., . . . Benazzo, M. (2016). European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: Results of the treatment of skin cancer. European Journal of Cancer, 63, 41-52. doi:https://doi.org/10.1016/j.ejca.2016.05.001

Besser, M. J., Shapira-Frommer, R., Treves, A. J., Zippel, D., Itzhaki, O., Hershkovitz, L., . . . Schachter, J. (2010). Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res, 16(9), 2646-2655. doi:10.1158/1078-0432.ccr-10-0041

Beutel, M. E., Fischbeck, S., Binder, H., Blettner, M., Brahler, E., Emrich, K., . . . Zeissig, S. R. (2015). Depression, anxiety and quality of life in long-term survivors of malignant melanoma: a register-based cohort study. PLoS One, 10(1), e0116440. doi:10.1371/journal.pone.0116440

Bibault, J. E., Dewas, S., Mirabel, X., Mortier, L., Penel, N., Vanseymortier, L., & Lartigau, E. (2011). Adjuvant radiation therapy in metastatic lymph nodes from melanoma. Radiat Oncol, 6, 12. doi:10.1186/1748-717x-6-12

Blank, C. U., Rozeman, E. A., Fanchi, L. F., Sikorska, K., van de Wiel, B., Kvistborg, P., . . . Schumacher, T. N. (2018). Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med, 24(11), 1655-1661. doi:10.1038/s41591-018-0198-0

Blum, A., Ingvar, C., Avramidis, M., von Kannen, A., Menzies, S. W., Olsson, H., . . . Westerhoff, K. (2007). Time to diagnosis of melanoma: same trend in different continents. J Cutan Med Surg, 11(4), 137-144.

Borve, A., Dahlen Gyllencreutz, J., Terstappen, K., Johansson Backman, E., Aldenbratt, A., Danielsson, M., . . . Paoli, J. (2015). Smartphone teledermoscopy referrals: a novel process for improved triage of skin cancer patients. Acta Derm Venereol, 95(2), 186-190. doi:10.2340/00015555-1906

Bowling, J., Argenziano, G., Azenha, A., Bandic, J., Bergman, R., Blum, A., . . . Braun, R. P. (2007). Dermoscopy key points: recommendations from the international dermoscopy society. Dermatology, 214(1), 3-5. doi:10.1159/000096904

Boyle, D. A. (2003). Psychological adjustment to the melanoma experience. Semin Oncol Nurs, 19(1), 70-77.

Bradish, J. R., Richey, J. D., Post, K. M., Meehan, K., Sen, J. D., Malek, A. J., . . . Cheng, L. (2015). Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy. Mod Pathol, 28(4), 480-486. doi:10.1038/modpathol.2014.136

Bradley, K. A., Rubinsky, A. D., Sun, H., Bryson, C. L., Bishop, M. J., Blough, D. K., . . . Kivlahan, D. R. (2011). Alcohol screening and risk of postoperative complications in male VA patients undergoing major non-cardiac surgery. J Gen Intern Med, 26(2), 162-169. doi:10.1007/s11606-010-1475-x

Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., . . . Thompson, J. A. (2018). Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol, 36(17), 1714-1768. doi:10.1200/jco.2017.77.6385

Brandberg, Y., Aamdal, S., Bastholt, L., Hernberg, M., Stierner, U., von der Maase, H., & Hansson, J. (2012). Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b. Eur J Cancer, 48(13), 2012-2019. doi:10.1016/j.ejca.2011.11.019

Branstrom, R., Chang, Y. M., Kasparian, N., Affleck, P., Tibben, A., Aspinwall, L. G., . . . Newton-Bishop, J. (2010). Melanoma risk factors, perceived threat and intentional tanning: an international online survey. Eur J Cancer Prev, 19(3), 216-226. doi:10.1097/CEJ.0b013e3283354847

Branstrom, R., Kasparian, N. A., Chang, Y. M., Affleck, P., Tibben, A., Aspinwall, L. G., . . . Brandberg, Y. (2010). Predictors of sun protection behaviors and severe sunburn in an international online study. Cancer Epidemiol Biomarkers Prev, 19(9), 2199-2210. doi:10.1158/1055-9965.epi-10-0196

Bucheit, A. D., Hardy, J. T., Szender, J. B., & Glitza Oliva, I. C. (2020). Conception and viable twin pregnancy in a patient with metastatic melanoma while treated with CTLA-4 and PD-1 checkpoint inhibition. Melanoma Res, 30(4), 423-425. doi:10.1097/cmr.0000000000000657

Burmeister, B. H., Henderson, M. A., Ainslie, J., Fisher, R., Di Iulio, J., Smithers, B. M., . . . Thompson, J. F. (2012). Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol, 13(6), 589-597. doi:10.1016/s1470-2045(12)70138-9

Burotto, M., Gormaz, J. G., Samtani, S., Valls, N., Silva, R., Rojas, C., . . . de la Jara, C. (2018). Viable Pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy. Semin Oncol, 45(3), 164-169. doi:10.1053/j.seminoncol.2018.03.003

Bånghammar, A., & Severin, A.-C. (2015). Hudvård- och sårbehandling till patienter i samband med extern strålbehandling. En litteraturstudie. (Independent thesis Basic level (degree of Bachelor) Student thesis). Retrieved from http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-109190 DiVA database.

Campana, L. G., Testori, A., Curatolo, P., Quaglino, P., Mocellin, S., Framarini, M., . . . Bonadies, A. (2016). Treatment efficacy with electrochemotherapy: A multi-institutional prospective observational study on 376 patients with superficial tumors. Eur J Surg Oncol. doi:10.1016/j.ejso.2016.06.399

Carvajal, R. D., Antonescu, C. R., Wolchok, J. D., Chapman, P. B., Roman, R. A., Teitcher, J., . . . Schwartz, G. K. (2011). KIT as a therapeutic target in metastatic melanoma. Jama, 305(22), 2327-2334. doi:10.1001/jama.2011.746

Carvajal, R. D., Lawrence, D. P., Weber, J. S., Gajewski, T. F., Gonzalez, R., Lutzky, J., . . . Hodi, F. S. (2015). Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clin Cancer Res, 21(10), 2289-2296. doi:10.1158/1078-0432.ccr-14-1630

Ceballos, P. I., Ruiz-Maldonado, R., & Mihm, M. C., Jr. (1995). Melanoma in children. N Engl J Med, 332(10), 656-662. doi:10.1056/nejm199503093321007

Cerroni, L., Barnhill, R., Elder, D., Gottlieb, G., Heenan, P., Kutzner, H., . . . Kerl, H. (2010). Melanocytic tumors of uncertain malignant potential: results of a tutorial held at the XXIX Symposium of the International Society of Dermatopathology in Graz, October 2008. Am J Surg Pathol, 34(3), 314-326. doi:10.1097/PAS.0b013e3181cf7fa0

Chalan, P., Di Dalmazi, G., Pani, F., De Remigis, A., Corsello, A., & Caturegli, P. (2018). Thyroid dysfunctions secondary to cancer immunotherapy. J Endocrinol Invest, 41(6), 625-638. doi:10.1007/s40618-017-0778-8

Chang, L. S., Barroso-Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (2019). Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. Endocr Rev, 40(1), 17-65. doi:10.1210/er.2018-00006

Chapman, B. C., Gleisner, A., Kwak, J. J., Hosokawa, P., Paniccia, A., Merkow, J. S., . . . Kounalakis, N. (2016). SPECT/CT Improves Detection of Metastatic Sentinel Lymph Nodes in Patients with Head and Neck Melanoma. Ann Surg Oncol, 23(8), 2652-2657. doi:10.1245/s10434-016-5175-6

Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., . . . McArthur, G. A. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med, 364(26), 2507-2516. doi:10.1056/NEJMoa1103782

Chapman, P. B., Robert, C., Larkin, J., Haanen, J. B., Ribas, A., Hogg, D., . . . McArthur, G. A. (2017). Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Ann Oncol, 28(10), 2581-2587. doi:10.1093/annonc/mdx339

Clark, W. H., Jr., From, L., Bernardino, E. A., & Mihm, M. C. (1969). The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res, 29(3), 705-727.

Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand. (2008). Retrieved from http://www.cancer.org.au/content/pdf/HealthProfessionals/ClinicalGuidelines/ClinicalPracticeGuidelines-ManagementofMelanoma.pdf

Clinical practice guidelines for the management of melanoma in Australia and new Zealand. (2009).

Cochran, A. M., Buchanan, P. J., Bueno, R. A., Jr., & Neumeister, M. W. (2014). Subungual melanoma: a review of current treatment. Plast Reconstr Surg, 134(2), 259-273. doi:10.1097/prs.0000000000000529

Cocorocchio, E., Pala, L., Battaglia, A., Gandini, S., Peccatori, F. A., & Ferrucci, P. F. (2018). Fatherhood during dabrafenib and trametinib therapy for metastatic melanoma. Acta Oncol, 57(8), 1131-1133. doi:10.1080/0284186x.2018.1449251

Cohen, J. V., Alomari, A. K., Vortmeyer, A. O., Jilaveanu, L. B., Goldberg, S. B., Mahajan, A., . . . Kluger, H. M. (2016). Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment. Cancer Immunol Res, 4(3), 179-182. doi:10.1158/2326-6066.cir-15-0160

Cohen, J. V., Tawbi, H., Margolin, K. A., Amravadi, R., Bosenberg, M., Brastianos, P. K., . . . Kluger, H. M. (2016). Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell Melanoma Res, 29(6), 627-642. doi:10.1111/pcmr.12538

Coit, D. G., Andtbacka, R., Bichakjian, C. K., Dilawari, R. A., Dimaio, D., Guild, V., . . . Wong, M. K. (2009). Melanoma. J Natl Compr Canc Netw, 7(3), 250-275.

Colaco, R. J., Martin, P., Kluger, H. M., Yu, J. B., & Chiang, V. L. (2016). Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases? J Neurosurg, 125(1), 17-23. doi:10.3171/2015.6.jns142763

Conen, K., Mosna-Firlejczyk, K., Rochlitz, C., Wicki, A., Itin, P., Arnold, A. W., . . . Zippelius, A. (2015). Vemurafenib-induced radiation recall dermatitis: case report and review of the literature. Dermatology, 230(1), 1-4. doi:10.1159/000365918

Curtin, J. A., Busam, K., Pinkel, D., & Bastian, B. C. (2006). Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol, 24(26), 4340-4346. doi:10.1200/jco.2006.06.2984

Czupryn, M., & Cisneros, J. (2017). BRAF/MEK Inhibitor Therapy: Consensus Statement From the Faculty of the Melanoma Nursing Initiative on Managing Adverse Events and Potential Drug Interactions. Clin J Oncol Nurs, 21(4 Suppl), 11-29. doi:10.1188/17.Cjon.S4.11-29

D'Angelo, S. P., Larkin, J., Sosman, J. A., Lebbe, C., Brady, B., Neyns, B., . . . Wolchok, J. D. (2017). Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. J Clin Oncol, 35(2), 226-235. doi:10.1200/jco.2016.67.9258

Daryanani, D., Plukker, J. T., Nap, R. E., Kuiper, H., & Hoekstra, H. J. (2006). Adolescent melanoma: risk factors and long term survival. Eur J Surg Oncol, 32(2), 218-223. doi:10.1016/j.ejso.2005.11.011

Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., . . . Futreal, P. A. (2002). Mutations of the BRAF gene in human cancer. Nature, 417(6892), 949-954. doi:10.1038/nature00766

Davies, J. R., Chang, Y. M., Bishop, D. T., Armstrong, B. K., Bataille, V., Bergman, W., . . . Newton-Bishop, J. (2015). Development and validation of a melanoma risk score based on pooled data from 16 case-control studies. Cancer Epidemiol Biomarkers Prev, 24(5), 817-824. doi:10.1158/1055-9965.epi-14-1062

Davies, L. M., Hayhurst, K. P., Lorigan, P., & Molassiotis, A. (2018). Unmet supportive care needs, health status and minimum costs in survivors of malignant melanoma. Eur J Cancer Care (Engl), 27(2), e12811. doi:10.1111/ecc.12811

Davies, M. A., Saiag, P., Robert, C., Grob, J. J., Flaherty, K. T., Arance, A., . . . Long, G. V. (2017). Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol, 18(7), 863-873. doi:10.1016/s1470-2045(17)30429-1

de Gruijl, F. R. (1999). Skin cancer and solar UV radiation. European Journal of Cancer, 35(14), 2003-2009. doi:https://doi.org/10.1016/S0959-8049(99)00283-X

Deroose, J. P., Grunhagen, D. J., Eggermont, A. M., & Verhoef, C. (2015). Repeated isolated limb perfusion in melanoma patients with recurrent in-transit metastases. Melanoma Res, 25(5), 427-431. doi:10.1097/cmr.0000000000000177

Dillman, R. O., Vandermolen, L. A., Barth, N. M., & Bransford, K. J. (1996). Malignant melanoma and pregnancy ten questions. West J Med, 164(2), 156-161.

Donnelly. (2003). Cutaneous malanoma: A national clinical guideline. 1 st ed 2003. Scottish Intercollegiate Guidelines Network:Edinburgh.

Driscoll, M. S., Martires, K., Bieber, A. K., Pomeranz, M. K., Grant-Kels, J. M., & Stein, J. A. (2016). Pregnancy and melanoma. J Am Acad Dermatol, 75(4), 669-678. doi:10.1016/j.jaad.2016.01.061

Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., . . . Rosenberg, S. A. (2005). Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol, 23(10), 2346-2357. doi:10.1200/jco.2005.00.240

Dudley, M. E., Yang, J. C., Sherry, R., Hughes, M. S., Royal, R., Kammula, U., . . . Rosenberg, S. A. (2008). Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol, 26(32), 5233-5239. doi:10.1200/jco.2008.16.5449

Duffy, K., & Grossman, D. (2012a). The dysplastic nevus: from historical perspective to management in the modern era: part I. Historical, histologic, and clinical aspects. J Am Acad Dermatol, 67(1), 1.e1-16; quiz 17-18. doi:10.1016/j.jaad.2012.02.047

Duffy, K., & Grossman, D. (2012b). The dysplastic nevus: from historical perspective to management in the modern era: part II. Molecular aspects and clinical management. J Am Acad Dermatol, 67(1), 19.e11-12; quiz 31-12. doi:10.1016/j.jaad.2012.03.013

Duma, N., Abdel-Ghani, A., Yadav, S., Hoversten, K. P., Reed, C. T., Sitek, A. N., . . . Dronca, R. S. (2019). Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal? Oncologist, 24(11), e1148-e1155. doi:10.1634/theoncologist.2019-0094

Duma, N., & Lambertini, M. (2020). It Is Time to Talk About Fertility and Immunotherapy. Oncologist, 25(4), 277-278. doi:10.1634/theoncologist.2019-0837

Dummer, R., Ascierto, P. A., Gogas, H. J., Arance, A., Mandala, M., Liszkay, G., . . . Flaherty, K. T. (2018). Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol, 19(5), 603-615. doi:10.1016/s1470-2045(18)30142-6

Dummer, R., Ascierto, P. A., Gogas, H. J., Arance, A., Mandala, M., Liszkay, G., . . . Flaherty, K. T. (2018). Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol, 19(10), 1315-1327. doi:10.1016/s1470-2045(18)30497-2

Dummer, R., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Kirkwood, J. M., . . . Schadendorf, D. (2020). Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. doi:10.1056/NEJMoa2005493

Dutton-Regester, K., & Hayward, N. K. (2012). Reviewing the somatic genetics of melanoma: from current to future analytical approaches. Pigment Cell Melanoma Res, 25(2), 144-154. doi:10.1111/j.1755-148X.2012.00975.x

Egberts, F., Bohne, A. S., Kruger, S., Hedderich, J., Rompel, R., Haag, J., . . . Hauschild, A. (2016). Varying Mutational Alterations in Multiple Primary Melanomas. J Mol Diagn, 18(1), 75-83. doi:10.1016/j.jmoldx.2015.07.010

Eggermont, A. M., Blank, C. U., Mandalà, M., Long, G. V., Atkinson, V., Dalle, S., . . . Robert, C. (2020). Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up. Journal of Clinical Oncology, 38(15_suppl), 10000-10000. doi:10.1200/JCO.2020.38.15_suppl.10000

Eggermont, A. M., Chiarion-Sileni, V., Grob, J. J., Dummer, R., Wolchok, J. D., Schmidt, H., . . . Testori, A. (2016). Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med. doi:10.1056/NEJMoa1611299

Eggermont, A. M., Suciu, S., Testori, A., Kruit, W. H., Marsden, J., Punt, C. J., . . . Spatz, A. (2012). Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer, 48(2), 218-225. doi:10.1016/j.ejca.2011.09.028

Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., . . . Robert, C. (2018). Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med, 378(19), 1789-1801. doi:10.1056/NEJMoa1802357

Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V. G., Dalle, S., . . . Robert, C. (2019). Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. European Journal of Cancer, 116, 148-157. doi:https://doi.org/10.1016/j.ejca.2019.05.020

El Ghissassi, F., Baan, R., Straif, K., Grosse, Y., Secretan, B., Bouvard, V., . . . Cogliano, V. (2009). A review of human carcinogens--part D: radiation. Lancet Oncol, 10(8), 751-752.

Elder, D., Massi, D., Scolyer, R., & Willemze, R. (2018). WHO Classification of Tumours (4th Edition ed. Vol. Volume 11): IARC.

Elder, D. E. (2011). Thin melanoma. Arch Pathol Lab Med, 135(3), 342-346. doi:10.1043/2009-0479-ra.1

Elder, D. E. (2016). Melanoma progression. Pathology, 48(2), 147-154. doi:10.1016/j.pathol.2015.12.002

Elder, D. E., & Xu, X. (2004). The approach to the patient with a difficult melanocytic lesion. Pathology, 36(5), 428-434. doi:10.1080/00313020412331283905

Emeny, J., Hansson, J., Toftgard, R., & Segerback, D. (2008). Meeting report of the conference on UV-Radiation-Induced Disease--Roles of UVA and UVB. J Invest Dermatol, 128(8), 1875-1877. doi:10.1038/jid.2008.180

Eriksson, H., Lyth, J., Mansson-Brahme, E., Frohm-Nilsson, M., Ingvar, C., Lindholm, C., . . . Hansson, J. (2014). Later stage at diagnosis and worse survival in cutaneous malignant melanoma among men living alone: a nationwide population-based study from Sweden. J Clin Oncol, 32(13), 1356-1364. doi:10.1200/jco.2013.52.7564

Eriksson, H., Lyth, J., Mansson-Brahme, E., Frohm-Nilsson, M., Ingvar, C., Lindholm, C., . . . Hansson, J. (2013). Low level of education is associated with later stage at diagnosis and reduced survival in cutaneous malignant melanoma: a nationwide population-based study in Sweden. Eur J Cancer, 49(12), 2705-2716. doi:10.1016/j.ejca.2013.03.013

Erim, Y., Loquai, C., Schultheis, U., Lindner, M., Beckmann, M., Schadendorf, C., & Senf, W. (2013). Anxiety, posttraumatic stress, and fear of cancer progression in patients with melanoma in cancer aftercare. Onkologie, 36(10), 540-544. doi:10.1159/000355137

Erman, A. B., Collar, R. M., Griffith, K. A., Lowe, L., Sabel, M. S., Bichakjian, C. K., . . . Bradford, C. R. (2012). Sentinel lymph node biopsy is accurate and prognostic in head and neck melanoma. Cancer, 118(4), 1040-1047. doi:10.1002/cncr.26288

Ethun, C. G., & Delman, K. A. (2016). The importance of surgical margins in melanoma. J Surg Oncol, 113(3), 339-345. doi:10.1002/jso.24111

Faithfull, S., Turner, L., Poole, K., Joy, M., Manders, R., Weprin, J., . . . Saxton, J. (2019). Prehabilitation for adults diagnosed with cancer: A systematic review of long-term physical function, nutrition and patient-reported outcomes. Eur J Cancer Care (Engl), 28(4), e13023. doi:10.1111/ecc.13023

Fang, P., Jiang, W., Allen, P., Glitza, I., Guha, N., Hwu, P., . . . Li, J. (2017). Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma. J Neurooncol, 133(3), 595-602. doi:10.1007/s11060-017-2470-4

Faries, M. B., Thompson, J. F., Cochran, A. J., Andtbacka, R. H., Mozzillo, N., Zager, J. S., . . . Elashoff, R. M. (2017). Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med, 376(23), 2211-2222. doi:10.1056/NEJMoa1613210

Farrahi, F., Egbert, B. M., & Swetter, S. M. (2005). Histologic similarities between lentigo maligna and dysplastic nevus: importance of clinicopathologic distinction. J Cutan Pathol, 32(6), 405-412. doi:10.1111/j.0303-6987.2005.00355.x

FDA  Food and Drug Administation. (2011). FDA. HIGHLIGHTS OF PRESCRIBING INFORMATION FOR VEMURAFENIB. US Food and Drug Administration 2011. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202429s012lbl.pdf

FDA  Food and Drug Administation. (2013a). FDA. HIGHLIGHTS OF PRESCRIBING INFORMATION FOR DABRAFENIB. US Food and Drug Administration 2013. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202806s002lbl.pdf

FDA  Food and Drug Administation. (2013b). FDA. HIGHLIGHTS OF PRESCRIBING INFORMATION FOR TRAMETINIB. US Food and Drug Administration 2013. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204114s007lbl.pdf

FDA  Food and Drug Administation. (2014). FDA. HIGHLIGHTS OF PRESCRIBING INFORMATION FOR NIVOLUMAB. US Food and Drug Administration 2014. . Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125554s081lbl.pdf

FDA  Food and Drug Administation. (2015). FDA. HIGHLIGHTS OF PRESCRIBING INFORMATION FOR IPILIMUMAB. US Food and Drug Administration 2011. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125377s073lbl.pdf

FDA  Food and Drug Administation. (2018a). FDA. HIGHLIGHTS OF PRESCRIBING INFORMATION FOR BINIMETINIB. US Food and Drug Administration 2018. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210498s001lbl.pdf

FDA  Food and Drug Administation. (2018b). FDA. HIGHLIGHTS OF PRESCRIBING INFORMATION FOR ENCORAFENIB. US Food and Drug Administration 2018. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf

Ferrone, C. R., Ben Porat, L., Panageas, K. S., Berwick, M., Halpern, A. C., Patel, A., & Coit, D. G. (2005). Clinicopathological features of and risk factors for multiple primary melanomas. Jama, 294(13), 1647-1654. doi:10.1001/jama.294.13.1647

Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., . . . Weber, J. (2012). Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med, 367(18), 1694-1703. doi:10.1056/NEJMoa1210093

Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., . . . Chapman, P. B. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med, 363(9), 809-819. doi:10.1056/NEJMoa1002011

Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., . . . Schadendorf, D. (2012). Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med, 367(2), 107-114. doi:10.1056/NEJMoa1203421

Forschner, A., Zips, D., Schraml, C., Rocken, M., Iordanou, E., Leiter, U., . . . Meier, F. (2014). Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib. Melanoma Res, 24(5), 512-516. doi:10.1097/cmr.0000000000000078

Frakes, J. M., Figura, N. B., Ahmed, K. A., Juan, T. H., Patel, N., Latifi, K., . . . Etame, A. B. (2015). Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases. J Neurosurg, 123(5), 1261-1267. doi:10.3171/2014.12.jns141919

Francken, A. B., Accortt, N. A., Shaw, H. M., Colman, M. H., Wiener, M., Soong, S. J., . . . Thompson, J. F. (2008). Follow-up schedules after treatment for malignant melanoma. Br J Surg, 95(11), 1401-1407. doi:10.1002/bjs.6347

Friedman, C. F., Proverbs-Singh, T. A., & Postow, M. A. (2016). Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. JAMA Oncol, 2(10), 1346-1353. doi:10.1001/jamaoncol.2016.1051

Friedman, J. F., Sunkara, B., Jehnsen, J. S., Durham, A., Johnson, T., & Cohen, M. S. (2015). Risk factors associated with lymphedema after lymph node dissection in melanoma patients. Am J Surg, 210(6), 1178-1184; discussion 1184. doi:10.1016/j.amjsurg.2015.08.014

Gandini, S., Sera, F., Cattaruzza, M. S., Pasquini, P., Abeni, D., Boyle, P., & Melchi, C. F. (2005). Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer, 41(1), 28-44. doi:10.1016/j.ejca.2004.10.015

Gangadhar, T. C., & Vonderheide, R. H. (2014). Mitigating the toxic effects of anticancer immunotherapy. Nat Rev Clin Oncol, 11(2), 91-99. doi:10.1038/nrclinonc.2013.245

Garbe, C., Eigentler, T. K., Keilholz, U., Hauschild, A., & Kirkwood, J. M. (2011). Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist, 16(1), 5-24. doi:10.1634/theoncologist.2010-0190

Garbe, C., Paul, A., Kohler-Spath, H., Ellwanger, U., Stroebel, W., Schwarz, M., . . . Rassner, G. (2003). Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol, 21(3), 520-529.

Garbe, C., Peris, K., Hauschild, A., Saiag, P., Middleton, M., Spatz, A., . . . Eggermont, A. (2010). Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer, 46(2), 270-283. doi:10.1016/j.ejca.2009.10.032

Gerschenwald. (2004). Staging sytems for cutaneos melanomain textbook of Melanoma. Editors martin Dunitz: London, 172.

Gershenwald, J. E., Scolyer, R. A., Hess, K. R., Sondak, V. K., Long, G. V., Ross, M. I., . . . Thompson, J. F. (2017). Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin, 67(6), 472-492. doi:10.3322/caac.21409

Gershenwald JE, S. R., Hess KR, et al. (2017). Melanoma of the Skin. In: AJCC Cancer Staging (

ed.). Chicago: American Joint Committee on Cancer,.

Ghezzi, M., Garolla, A., Magagna, S., Šabovich, I., Berretta, M., Foresta, C., & De Toni, L. (2020). Fertility Outcomes and Sperm-DNA Parameters in Metastatic Melanoma Survivors Receiving Vemurafenib or Dabrafenib Therapy: Case Report. Front Oncol, 10, 232. doi:10.3389/fonc.2020.00232

Ghiasvand, R., Weiderpass, E., Green, A. C., Lund, E., & Veierod, M. B. (2016). Sunscreen Use and Subsequent Melanoma Risk: A Population-Based Cohort Study. J Clin Oncol. doi:10.1200/jco.2016.67.5934

Global Cancer Observatory. Retrieved from http://gco.iarc.fr/

Goldberg, S. B., Gettinger, S. N., Mahajan, A., Chiang, A. C., Herbst, R. S., Sznol, M., . . . Kluger, H. M. (2016). Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol, 17(7), 976-983. doi:10.1016/s1470-2045(16)30053-5

Gomez-Rivera, F., Santillan, A., McMurphey, A. B., Paraskevopoulos, G., Roberts, D. B., Prieto, V. G., & Myers, J. N. (2008). Sentinel node biopsy in patients with cutaneous melanoma of the head and neck: recurrence and survival study. Head Neck, 30(10), 1284-1294. doi:10.1002/hed.20875

Gondi, V., Pugh, S. L., Tome, W. A., Caine, C., Corn, B., Kanner, A., . . . Mehta, M. P. (2014). Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol, 32(34), 3810-3816. doi:10.1200/jco.2014.57.2909

Green, A. C., Williams, G. M., Logan, V., & Strutton, G. M. (2011). Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol, 29(3), 257-263. doi:10.1200/jco.2010.28.7078

Greene, G. (2002). AJCC cancer staging manual 6th ed. Springer New York.

Grin, C. M., Rojas, A. I., & Grant-Kels, J. M. (2001). Does pregnancy alter melanocytic nevi? J Cutan Pathol, 28(8), 389-392.

Gunduz, K., Koltan, S., Sahin, M. T., & E, E. F. (2003). Analysis of melanocytic naevi by dermoscopy during pregnancy. J Eur Acad Dermatol Venereol, 17(3), 349-351.

Guo, J., Carvajal, R. D., Dummer, R., Hauschild, A., Daud, A., Bastian, B. C., . . . Hodi, F. S. (2017). Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial. Ann Oncol, 28(6), 1380-1387. doi:10.1093/annonc/mdx079

Guo, J., Si, L., Kong, Y., Flaherty, K. T., Xu, X., Zhu, Y., . . . Qin, S. (2011). Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol, 29(21), 2904-2909. doi:10.1200/jco.2010.33.9275

Haanen, J., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2018). Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 29(Suppl 4), iv264-iv266. doi:10.1093/annonc/mdy162

Haenssle, H. A., Krueger, U., Vente, C., Thoms, K. M., Bertsch, H. P., Zutt, M., . . . Emmert, S. (2006). Results from an observational trial: digital epiluminescence microscopy follow-up of atypical nevi increases the sensitivity and the chance of success of conventional dermoscopy in detecting melanoma. J Invest Dermatol, 126(5), 980-985. doi:10.1038/sj.jid.5700119

Hafstrom, A., Romell, A., Ingvar, C., Wahlberg, P., & Greiff, L. (2016). Sentinel lymph node biopsy staging for cutaneous malignant melanoma of the head and neck. Acta Otolaryngol, 136(3), 312-318. doi:10.3109/00016489.2015.1113559

Hajdarevic, S., Rasmussen, B. H., & Hornsten, A. (2014). You never know when your last day will come and your trip will be over--existential expressions from a melanoma diagnosis. Eur J Oncol Nurs, 18(4), 355-361. doi:10.1016/j.ejon.2014.03.015

Hajdarevic, S., Schmitt-Egenolf, M., Brulin, C., Sundbom, E., & Hornsten, A. (2011). Malignant melanoma: gender patterns in care seeking for suspect marks. J Clin Nurs, 20(17-18), 2676-2684. doi:10.1111/j.1365-2702.2011.03788.x

Hajdarevic, S., Schmitt-Egenolf, M., Sundbom, E., Isaksson, U., & Hornsten, A. (2013). Coping styles in decision-making among men and women diagnosed with malignant melanoma. J Health Psychol, 18(11), 1445-1455. doi:10.1177/1359105312464671

Hall, R., Manski-Nankervis, J., Goni, N., Davies, M. C., & Conway, G. S. (2006). Fertility outcomes in women with hypopituitarism. Clin Endocrinol (Oxf), 65(1), 71-74. doi:10.1111/j.1365-2265.2006.02550.x

Hamid, O., Robert, C., Ribas, A., Hodi, F. S., Walpole, E., Daud, A., . . . Butler, M. (2018). Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. Br J Cancer, 119(6), 670-674. doi:10.1038/s41416-018-0207-6

Hansson, J., Aamdal, S., Bastholt, L., Brandberg, Y., Hernberg, M., Nilsson, B., . . . von der Maase, H. (2011). Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. Lancet Oncol, 12(2), 144-152. doi:10.1016/s1470-2045(10)70288-6

Hansson, J., Bergenmar, M., Hofer, P. A., Lundell, G., Mansson-Brahme, E., Ringborg, U., . . . Rosdahl, I. (2007). Monitoring of kindreds with hereditary predisposition for cutaneous melanoma and dysplastic nevus syndrome: results of a Swedish preventive program. J Clin Oncol, 25(19), 2819-2824. doi:10.1200/jco.2007.11.4108

Hauschild, A., Dummer, R., Schadendorf, D., Santinami, M., Atkinson, V., Mandala, M., . . . Long, G. V. (2018). Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma. J Clin Oncol, Jco1801219. doi:10.1200/jco.18.01219

Hauschild, A., Grob, J. J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., . . . Chapman, P. B. (2012). Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet, 380(9839), 358-365. doi:10.1016/s0140-6736(12)60868-x

Hecht, M., Meier, F., Zimmer, L., Polat, B., Loquai, C., Weishaupt, C., . . . Heinzerling, L. (2018). Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients. Br J Cancer, 118(6), 785-792. doi:10.1038/bjc.2017.489

Hedblad, M. A., & Mallbris, L. (2012). Grenz ray treatment of lentigo maligna and early lentigo maligna melanoma. J Am Acad Dermatol, 67(1), 60-68. doi:10.1016/j.jaad.2011.06.029

Heenan, P. J., & Ghaznawie, M. (1999). The pathogenesis of local recurrence of melanoma at the primary excision site. Br J Plast Surg, 52(3), 209-213. doi:10.1054/bjps.1998.3050

Helgadottir, H., Hoiom, V., Jonsson, G., Tuominen, R., Ingvar, C., Borg, A., . . . Hansson, J. (2014). High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families. J Med Genet, 51(8), 545-552. doi:10.1136/jmedgenet-2014-102320

Helgadottir, H., Hoiom, V., Tuominen, R., Jonsson, G., Mansson-Brahme, E., Olsson, H., & Hansson, J. (2015). CDKN2a mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies. Int J Cancer, 137(9), 2220-2226. doi:10.1002/ijc.29595

Henderson, M. A., Burmeister, B. H., Ainslie, J., Fisher, R., Di Iulio, J., Smithers, B. M., . . . Thompson, J. F. (2015). Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncol, 16(9), 1049-1060. doi:10.1016/s1470-2045(15)00187-4

Hersh, E. M., Del Vecchio, M., Brown, M. P., Kefford, R., Loquai, C., Testori, A., . . . Hauschild, A. (2015). A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma. Ann Oncol, 26(11), 2267-2274. doi:10.1093/annonc/mdv324

Hodi, F. S., Corless, C. L., Giobbie-Hurder, A., Fletcher, J. A., Zhu, M., Marino-Enriquez, A., . . . Fisher, D. E. (2013). Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol, 31(26), 3182-3190. doi:10.1200/jco.2012.47.7836

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., . . . Urba, W. J. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 363(8), 711-723. doi:10.1056/NEJMoa1003466

Holterhues, C., Cornish, D., van de Poll-Franse, L. V., Krekels, G., Koedijk, F., Kuijpers, D., . . . Nijsten, T. (2011). Impact of melanoma on patients' lives among 562 survivors: a Dutch population-based study. Arch Dermatol, 147(2), 177-185. doi:10.1001/archdermatol.2010.433

Houriet, C., Klass, N. D., Beltraminelli, H., Borradori, L., & Oberholzer, P. A. (2014). Localized Epidermal Cysts as a Radiation Recall Phenomenon in a Melanoma Patient Treated with Radiotherapy and the BRAF Inhibitor Vemurafenib. Case Rep Dermatol, 6(3), 213-217. doi:10.1159/000367708

Hudmelanom - Årsrapport nationellt kvalitetsregister. Diagnosår 1990-2016. (2017). Retrieved from https://www.cancercentrum.se/samverkan/cancerdiagnoser/hud-och-ogon/kvalitetsregister/

Hultstrand Ahlin, C., Hörnsten, Å., Coe, A.-B., Lilja, M., & Hajdarevic, S. (2019). Wishing to be perceived as a capable and resourceful person—A qualitative study of melanoma patients’ experiences of the contact and interaction with healthcare professionals. 28(7-8), 1223-1232. doi:10.1111/jocn.14730

Hunter, G. K., Suh, J. H., Reuther, A. M., Vogelbaum, M. A., Barnett, G. H., Angelov, L., . . . Chao, S. T. (2012). Treatment of five or more brain metastases with stereotactic radiosurgery. Int J Radiat Oncol Biol Phys, 83(5), 1394-1398. doi:10.1016/j.ijrobp.2011.10.026

Iwakawa, M., Noda, S., Yamada, S., Yamamoto, N., Miyazawa, Y., Yamazaki, H., . . . Imai, T. (2006). Analysis of non-genetic risk factors for adverse skin reactions to radiotherapy among 284 breast cancer patients. Breast Cancer, 13(3), 300-307.

Jagsi, R., Griffith, K. A., Koelling, T., Roberts, R., & Pierce, L. J. (2007). Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer. Cancer, 109(4), 650-657. doi:10.1002/cncr.22452

Jillela. (1995). The role for close follow-up of melanoma patients with AJCC stage I-III: a prelimary analysis: Proc Am Soc Clin Oncol.

Kalinsky, K., Lee, S., Rubin, K. M., Lawrence, D. P., Iafrarte, A. J., Borger, D. R., . . . Kirkwood, J. M. (2017). A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607). Cancer, 123(14), 2688-2697. doi:10.1002/cncr.30663

Karimipour, D. J., Schwartz, J. L., Wang, T. S., Bichakjian, C. K., Orringer, J. S., King, A. L., . . . Johnson, T. M. (2005). Microstaging accuracy after subtotal incisional biopsy of cutaneous melanoma. J Am Acad Dermatol, 52(5), 798-802. doi:10.1016/j.jaad.2004.09.031

Karlsson, M. (2015). Sun Exposure, Prevalence and Localization of Common Melanocytic Naevi in Swedish Children (Vol. B. Karlsson M, and Institutionen För Medicin, Solna. Sun Exposure, Prevalence and Localization of Common Melanocytic Naevi in Swedish Children (2015)). Solna: Institutionen För Medicin, Karolinska Institutet.

Karlsson, P., Boeryd, B., Sander, B., Westermark, P., & Rosdahl, I. (1998). Increasing incidence of cutaneous malignant melanoma in children and adolescents 12-19 years of age in Sweden 1973-92. Acta Derm Venereol, 78(4), 289-292.

Karlsson, P. M., & Fredrikson, M. (2007). Cutaneous malignant melanoma in children and adolescents in Sweden, 1993-2002: the increasing trend is broken. Int J Cancer, 121(2), 323-328. doi:10.1002/ijc.22692

Kasparian, N. A. (2013). Psychological Care for People with Melanoma: What, When, Why and How? Semin Oncol Nurs, 29(3), 214-222. doi:https://doi.org/10.1016/j.soncn.2013.06.007

Katz, V. L., Farmer, R. M., & Dotters, D. (2002). Focus on primary care: from nevus to neoplasm: myths of melanoma in pregnancy. Obstet Gynecol Surv, 57(2), 112-119.

Kaufman, E. L., Jacobson, J. S., Hershman, D. L., Desai, M., & Neugut, A. I. (2008). Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J Clin Oncol, 26(3), 392-398. doi:10.1200/jco.2007.13.3033

Keilholz, U., Ascierto, P. A., Dummer, R., Robert, C., Lorigan, P., van Akkooi, A., . . . Michielin, O. (2020). ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Annals of Oncology. doi:https://doi.org/10.1016/j.annonc.2020.07.004

Kersey, P. A., Iscoe, N. A., Gapski, J. A., Osoba, D., From, L., DeBoer, G., & Quirt, I. C. (1985). The value of staging and serial follow-up investigations in patients with completely resected, primary, cutaneous malignant melanoma. Br J Surg, 72(8), 614-617.

Kiebert, G. M., Jonas, D. L., & Middleton, M. R. (2003). Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine. Cancer Invest, 21(6), 821-829.

Kiess, A. P., Wolchok, J. D., Barker, C. A., Postow, M. A., Tabar, V., Huse, J. T., . . . Beal, K. (2015). Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys, 92(2), 368-375. doi:10.1016/j.ijrobp.2015.01.004

Kilic, E., Bruggenwirth, H. T., Verbiest, M. M., Zwarthoff, E. C., Mooy, N. M., Luyten, G. P., & de Klein, A. (2004). The RAS-BRAF kinase pathway is not involved in uveal melanoma. Melanoma Res, 14(3), 203-205.

Kimsey, T. F., Cohen, T., Patel, A., Busam, K. J., & Brady, M. S. (2009). Microscopic satellitosis in patients with primary cutaneous melanoma: implications for nodal basin staging. Ann Surg Oncol, 16(5), 1176-1183. doi:10.1245/s10434-009-0350-7

Kirkwood, J. M., Ibrahim, J. G., Sondak, V. K., Richards, J., Flaherty, L. E., Ernstoff, M. S., . . . Blum, R. H. (2000). High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol, 18(12), 2444-2458.

Kirkwood, J. M., Manola, J., Ibrahim, J., Sondak, V., Ernstoff, M. S., & Rao, U. (2004). A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res, 10(5), 1670-1677.

Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C., & Blum, R. H. (1996). Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol, 14(1), 7-17. doi:10.1200/jco.1996.14.1.7

Kirova, Y. M., Chen, J., Rabarijaona, L. I., Piedbois, Y., & Le Bourgeois, J. P. (1999). Radiotherapy as palliative treatment for metastatic melanoma. Melanoma Res, 9(6), 611-613.

Kittler, H., Guitera, P., Riedl, E., Avramidis, M., Teban, L., Fiebiger, M., . . . Menzies, S. (2006). Identification of clinically featureless incipient melanoma using sequential dermoscopy imaging. Arch Dermatol, 142(9), 1113-1119. doi:10.1001/archderm.142.9.1113

Kittler, H., Pehamberger, H., Wolff, K., & Binder, M. (2002). Diagnostic accuracy of dermoscopy. Lancet Oncol, 3(3), 159-165.

Koops, H. S., Vaglini, M., Suciu, S., Kroon, B. B., Thompson, J. F., Gohl, J., . . . Lejeune, F. J. (1998). Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol, 16(9), 2906-2912.

Kossard, S. (2002). Atypical lentiginous junctional naevi of the elderly and melanoma. Australas J Dermatol, 43(2), 93-101.

Kottschade, L. A., & Lehner Reed, M. (2017). Promoting Oral Therapy Adherence: Consensus Statements From the Faculty of the Melanoma Nursing Initiative on Oral Melanoma Therapies. Clin J Oncol Nurs, 21(4 Suppl), 87-96. doi:10.1188/17.Cjon.S4.87-96

Koyyada, A., & Orsu, P. (2020). Role of hypothyroidism and associated pathways in pregnancy and infertility: Clinical insights. Tzu Chi Med J, 32(4), 312-317. doi:10.4103/tcmj.tcmj_255_19

Krajewska-Kulak, E., & Sengupta, P. (2013). Thyroid function in male infertility. Front Endocrinol (Lausanne), 4, 174. doi:10.3389/fendo.2013.00174

Kunishige, J. H., Brodland, D. G., & Zitelli, J. A. (2012). Surgical margins for melanoma in situ. J Am Acad Dermatol, 66(3), 438-444. doi:10.1016/j.jaad.2011.06.019

Kupferman, M. E., Kubik, M. W., Bradford, C. R., Civantos, F. J., Devaney, K. O., Medina, J. E., . . . Ferlito, A. (2014). The role of sentinel lymph node biopsy for thin cutaneous melanomas of the head and neck. Am J Otolaryngol, 35(2), 226-232. doi:10.1016/j.amjoto.2013.12.004

Lallas, A., Kyrgidis, A., Ferrara, G., Kittler, H., Apalla, Z., Castagnetti, F., . . . Argenziano, G. (2014). Atypical Spitz tumours and sentinel lymph node biopsy: a systematic review. Lancet Oncol, 15(4), e178-183. doi:10.1016/s1470-2045(13)70608-9

Lange, J. R., Palis, B. E., Chang, D. C., Soong, S. J., & Balch, C. M. (2007). Melanoma in children and teenagers: an analysis of patients from the National Cancer Data Base. J Clin Oncol, 25(11), 1363-1368. doi:10.1200/jco.2006.08.8310

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., . . . Wolchok, J. D. (2015). Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med, 373(1), 23-34. doi:10.1056/NEJMoa1504030

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Rutkowski, P., Lao, C. D., . . . Wolchok, J. D. (2019). Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med, 381(16), 1535-1546. doi:10.1056/NEJMoa1910836

Larkin, J., Hodi, F. S., & Wolchok, J. D. (2015). Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med, 373(13), 1270-1271. doi:10.1056/NEJMc1509660

Larkin, J., Minor, D., D'Angelo, S., Neyns, B., Smylie, M., Miller, W. H., Jr., . . . Weber, J. (2017). Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. J Clin Oncol, Jco2016718023. doi:10.1200/jco.2016.71.8023

Lasa-Blandon, M., Stasi, K., Hehir, A., & Fischer-Cartlidge, E. (2019). Patient Education Issues and Strategies Associated With Immunotherapy. Semin Oncol Nurs, 35(5), 150933. doi:10.1016/j.soncn.2019.08.012

Lebbe, C., Meyer, N., Mortier, L., Marquez-Rodas, I., Robert, C., Rutkowski, P., . . . Pigozzo, J. (2019). Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. J Clin Oncol, 37(11), 867-875. doi:10.1200/jco.18.01998

Lee, C. C., Faries, M. B., Wanek, L. A., & Morton, D. L. (2008). Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol, 26(4), 535-541. doi:10.1200/jco.2007.14.0285

Lee, S. J., Kim, T. M., Kim, Y. J., Jang, K. T., Lee, H. J., Lee, S. N., . . . Lee, J. (2015). Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06). Oncologist, 20(11), 1312-1319. doi:10.1634/theoncologist.2015-0161

Lee, S. M., Betticher, D. C., & Thatcher, N. (1995). Melanoma: chemotherapy. Br Med Bull, 51(3), 609-630.

Leiter, U., Stadler, R., Mauch, C., Hohenberger, W., Brockmeyer, N., Berking, C., . . . Garbe, C. (2016). Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol, 17(6), 757-767. doi:10.1016/s1470-2045(16)00141-8

Leman, J. A., Evans, A., Mooi, W., & MacKie, R. M. (2005). Outcomes and pathological review of a cohort of children with melanoma. Br J Dermatol, 152(6), 1321-1323. doi:10.1111/j.1365-2133.2005.06609.x

Lens, M., Rosdahl, I., & Newton-Bishop, J. (2009). Cutaneous melanoma during pregnancy: is the controversy over? J Clin Oncol, 27(19), e11-12; author reply e13-14. doi:10.1200/jco.2009.22.2588

Lens, M. B., Rosdahl, I., Ahlbom, A., Farahmand, B. Y., Synnerstad, I., Boeryd, B., & Newton Bishop, J. A. (2004). Effect of pregnancy on survival in women with cutaneous malignant melanoma. J Clin Oncol, 22(21), 4369-4375. doi:10.1200/jco.2004.02.096

Lindholm, C., Andersson, R., Dufmats, M., Hansson, J., Ingvar, C., Moller, T., . . . Wagenius, G. (2004). Invasive cutaneous malignant melanoma in Sweden, 1990-1999. A prospective, population-based study of survival and prognostic factors. Cancer, 101(9), 2067-2078. doi:10.1002/cncr.20602

Liniker, E., Menzies, A. M., Kong, B. Y., Cooper, A., Ramanujam, S., Lo, S., . . . Long, G. V. (2016). Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. Oncoimmunology, 5(9), e1214788. doi:10.1080/2162402x.2016.1214788

Livestro, D. P., Kaine, E. M., Michaelson, J. S., Mihm, M. C., Haluska, F. G., Muzikansky, A., . . . Tanabe, K. K. (2007). Melanoma in the young: Differences and similarities with adult melanoma. Cancer, 110(3), 614-624. doi:10.1002/cncr.22818

Long, G. V., Atkinson, V., Lo, S., Sandhu, S., Guminski, A. D., Brown, M. P., . . . McArthur, G. A. (2018). Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol, 19(5), 672-681. doi:10.1016/s1470-2045(18)30139-6

Long, G. V., Hauschild, A., Santinami, M., Atkinson, V., Mandala, M., Chiarion-Sileni, V., . . . Kirkwood, J. M. (2017). Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. doi:10.1056/NEJMoa1708539

Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., . . . Flaherty, K. (2015). Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet, 386(9992), 444-451. doi:10.1016/s0140-6736(15)60898-4

Loquai, C., Schmidtmann, I., Beutel, M., Sunderkotter, C., Grabbe, S., Schiller, M., & Nashan, D. (2011). Quality of life in melanoma patients during adjuvant treatment with pegylated interferon-alpha2b: patients' and doctors' views. Eur J Dermatol, 21(6), 976-984. doi:10.1684/ejd.2011.1514

Luo, S., Lobo, A. Z., Tanabe, K. K., Muzikansky, A., Durazzo, T., Sober, A., . . . Duncan, L. M. (2015). Clinical significance of microscopic melanoma metastases in the nonhottest sentinel lymph nodes. JAMA Surg, 150(5), 465-472. doi:10.1001/jamasurg.2014.3843

Lyth, J., Hansson, J., Ingvar, C., Mansson-Brahme, E., Naredi, P., Stierner, U., . . . Lindholm, C. (2013). Prognostic subclassifications of T1 cutaneous melanomas based on ulceration, tumour thickness and Clark's level of invasion: results of a population-based study from the Swedish Melanoma Register. Br J Dermatol, 168(4), 779-786. doi:10.1111/bjd.12095

Lyth, J., Mikiver, R., Nielsen, K., Isaksson, K., & Ingvar, C. (2016). Prognostic instrument for survival outcome in melanoma patients: based on data from the population-based Swedish Melanoma Register. Eur J Cancer, 59, 171-178. doi:10.1016/j.ejca.2016.02.029

Macdonald, G., Kondor, N., Yousefi, V., Green, A., Wong, F., & Aquino-Parsons, C. (2004). Reduction of carboxyhaemoglobin levels in the venous blood of cigarette smokers following the administration of carbogen. Radiother Oncol, 73(3), 367-371. doi:10.1016/j.radonc.2004.09.002

MacKie, R. M., Bufalino, R., Morabito, A., Sutherland, C., & Cascinelli, N. (1991). Lack of effect of pregnancy on outcome of melanoma. For The World Health Organisation Melanoma Programme. Lancet, 337(8742), 653-655.

Madden, K., & Kasler, M. K. (2019). Immune Checkpoint Inhibitors in Lung Cancer and Melanoma. Semin Oncol Nurs, 35(5), 150932. doi:10.1016/j.soncn.2019.08.011

Madden, K. M., & Hoffner, B. (2017). Ipilimumab-Based Therapy: Consensus Statement From the Faculty of the Melanoma Nursing Initiative on Managing Adverse Events With Ipilimumab Monotherapy and Combination Therapy With Nivolumab. Clin J Oncol Nurs, 21(4 Suppl), 30-41. doi:10.1188/17.Cjon.S4.30-41

Mahvi, D. A., Fairweather, M., Yoon, C. H., & Cho, N. L. (2019). Utility of Level III Axillary Node Dissection in Melanoma Patients with Palpable Axillary Lymph Node Disease. Ann Surg Oncol, 26(9), 2846-2854. doi:10.1245/s10434-019-07509-2

Maio, M., Lewis, K., Demidov, L., Mandalà, M., Bondarenko, I., Ascierto, P. A., . . . Schadendorf, D. (2018). Adjuvant vemurafenib in resected, BRAF(V600) mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol, 19(4), 510-520. doi:10.1016/s1470-2045(18)30106-2

Maleka, A., Enblad, G., Sjors, G., Lindqvist, A., & Ullenhag, G. J. (2013). Treatment of metastatic malignant melanoma with vemurafenib during pregnancy. J Clin Oncol, 31(11), e192-193. doi:10.1200/jco.2012.45.2870

Maleka, A., Enblad, G., Sjörs, G., Lindqvist, A., & Ullenhag, G. J. (2013). Treatment of metastatic malignant melanoma with vemurafenib during pregnancy. J Clin Oncol, 31(11), e192-193. doi:10.1200/jco.2012.45.2870

Malekzadeh, F., et al. (2005). Naturläkemedel och hormonpreparat - potentiell risk för bröstcancerpatienter 102.

Malignant Melanoma of Skin. In: TNM Classification of Malignant Tumours. (2017).  (D. Brierley, M. Gospodarowicz, & C. Wittekind Eds. 8th edition ed.).

Marcé, D., Cornillier, H., Denis, C., Jonville-Bera, A. P., & Machet, L. (2019). Partial response of metastatic melanoma to BRAF-inhibitor-monotherapy in a pregnant patient with no fetal toxicity. Melanoma Res, 29(4), 446-447. doi:10.1097/cmr.0000000000000600

Marsden, J. R., Newton-Bishop, J. A., Burrows, L., Cook, M., Corrie, P. G., Cox, N. H., . . . Walker, C. (2010). Revised U.K. guidelines for the management of cutaneous melanoma 2010. Br J Dermatol, 163(2), 238-256. doi:10.1111/j.1365-2133.2010.09883.x

Martin, R. C., 2nd, Scoggins, C. R., Ross, M. I., Reintgen, D. S., Noyes, R. D., Edwards, M. J., & McMasters, K. M. (2005). Is incisional biopsy of melanoma harmful? Am J Surg, 190(6), 913-917. doi:10.1016/j.amjsurg.2005.08.020

Martya, M. (2006). Electrochemotherapy – An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard OperatingProcedures of Electrochemotherapy) study: European Journal of Cancer.

Mattsson, J., Bergkvist, L., Abdiu, A., Aili Low, J. F., Naredi, P., Ullberg, K., . . . Ingvar, C. (2008). Sentinel node biopsy in malignant melanoma: Swedish experiences 1997-2005. Acta Oncol, 47(8), 1519-1525. doi:10.1080/02841860701785533

McArthur, G. A., Chapman, P. B., Robert, C., Larkin, J., Haanen, J. B., Dummer, R., . . . Hauschild, A. (2014). Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol, 15(3), 323-332. doi:10.1016/s1470-2045(14)70012-9

McGettigan, S., & Rubin, K. M. (2017). PD-1 Inhibitor Therapy: Consensus Statement From the Faculty of the Melanoma Nursing Initiative on Managing Adverse Events. Clin J Oncol Nurs, 21(4 Suppl), 42-51. doi:10.1188/17.Cjon.S4.42-51

McLoone, J., Watts, K., Menzies, S., Meiser, B., Butow, P., & Kasparian, N. (2012). When the risks are high: psychological adjustment among melanoma survivors at high risk of developing new primary disease. Qual Health Res, 22(8), 1102-1113. doi:10.1177/1049732312448542

McPherson, M., Elwood, M., English, D. R., Baade, P. D., Youl, P. H., & Aitken, J. F. (2006). Presentation and detection of invasive melanoma in a high-risk population. J Am Acad Dermatol, 54(5), 783-792. doi:10.1016/j.jaad.2005.08.065

MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma (MelmarT). Retrieved from https://clinicaltrials.gov/ct2/show/NCT02385214

Menzer, C., Beedgen, B., Rom, J., Duffert, C. M., Volckmar, A. L., Sedlaczek, O., . . . Hassel, J. C. (2018). Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy. Eur J Cancer, 104, 239-242. doi:10.1016/j.ejca.2018.09.008

Menzies, A. (2003). Dermatoscopy. An Atlas of Surface Microscopy of Pigmented Skin Lesions. (Vol. 2nd ). Sidney: McGraw-Hill.

Menzies, S. W., Gutenev, A., Avramidis, M., Batrac, A., & McCarthy, W. H. (2001). Short-term digital surface microscopic monitoring of atypical or changing melanocytic lesions. Arch Dermatol, 137(12), 1583-1589.

Menzies, S. W., & Zalaudek, I. (2006). Why perform dermoscopy? The evidence for its role in the routine management of pigmented skin lesions. Arch Dermatol, 142(9), 1211-1212. doi:10.1001/archderm.142.9.1211

Michielin, O., van Akkooi, A., Lorigan, P., Ascierto, P. A., Dummer, R., Robert, C., . . . Keilholz, U. (2020). ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. Annals of Oncology. doi:https://doi.org/10.1016/j.annonc.2020.07.005

Mills, O., & Messina, J. L. (2009). Pediatric melanoma: a review. Cancer Control, 16(3), 225-233.

Milne, D., Hyatt, A., Billett, A., Gough, K., & Krishnasamy, M. (2020). Exploring the Experiences of People Treated With Immunotherapies for Advanced Melanoma and Those Caring for Them: "Real-World" Data. Cancer Nurs, 43(2), E97-e104. doi:10.1097/ncc.0000000000000683

Moehrle, M., Metzger, S., Schippert, W., Garbe, C., Rassner, G., & Breuninger, H. (2003). "Functional" surgery in subungual melanoma. Dermatol Surg, 29(4), 366-374.

Mohammadi, A. M., Recinos, P. F., Barnett, G. H., Weil, R. J., Vogelbaum, M. A., Chao, S. T., . . . Angelov, L. (2012). Role of Gamma Knife surgery in patients with 5 or more brain metastases. J Neurosurg, 117 Suppl, 5-12. doi:10.3171/2012.8.gks12983

Molassiotis, A., Brunton, L., Hodgetts, J., Green, A. C., Beesley, V. L., Mulatero, C., . . . Lorigan, P. (2014). Prevalence and correlates of unmet supportive care needs in patients with resected invasive cutaneous melanoma. Annals of Oncology, 25(10), 2052-2058. doi:10.1093/annonc/mdu366

Moncrieff, M. D., O'Leary, F. M., Beadsmoore, C. J., Pawaroo, D., Heaton, M. J., Isaksson, K., & Olofsson Bagge, R. (2020). Effect of delay between nuclear medicine scanning and sentinel node biopsy on outcome in patients with cutaneous melanoma. Br J Surg. doi:10.1002/bjs.11460

Moreno-Ramirez, D., de la Cruz-Merino, L., Ferrandiz, L., Villegas-Portero, R., & Nieto-Garcia, A. (2010). Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety. Oncologist, 15(4), 416-427. doi:10.1634/theoncologist.2009-0325

Morton, D. L., Thompson, J. F., Cochran, A. J., Mozzillo, N., Elashoff, R., Essner, R., . . . Wang, H. J. (2006). Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med, 355(13), 1307-1317. doi:10.1056/NEJMoa060992

Morton, D. L., Thompson, J. F., Cochran, A. J., Mozzillo, N., Nieweg, O. E., Roses, D. F., . . . Faries, M. B. (2014). Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med, 370(7), 599-609. doi:10.1056/NEJMoa1310460

Moseholm, E., Lindhardt, B. O., & Rydahl-Hansen, S. (2017). The experiences of health-related quality of life in patients with nonspecific symptoms who undergo a diagnostic evaluation for cancer: a qualitative interview study. Scand J Caring Sci, 31(3), 463-473. doi:10.1111/scs.12359

Moseholm, E., Rydahl-Hansen, S., Lindhardt, B. O., & Fetters, M. D. (2017). Health-related quality of life in patients with serious non-specific symptoms undergoing evaluation for possible cancer and their experience during the process: a mixed methods study. Qual Life Res, 26(4), 993-1006. doi:10.1007/s11136-016-1423-2

Murchie, P., Delaney, E. K., Campbell, N. C., & Hannaford, P. C. (2010). GP-led melanoma follow-up: views and feelings of patient recipients. Support Care Cancer, 18(2), 225-233. doi:10.1007/s00520-009-0648-9

Najjar, Y. G., Navrazhina, K., Ding, F., Bhatia, R., Tsai, K., Abbate, K., . . . Shoushtari, A. (2020). Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. J Immunother Cancer, 8(1). doi:10.1136/jitc-2019-000331

Nath, B., Li, Y., Carroll, J. E., Szabo, G., Tseng, J. F., & Shah, S. A. (2010). Alcohol exposure as a risk factor for adverse outcomes in elective surgery. J Gastrointest Surg, 14(11), 1732-1741. doi:10.1007/s11605-010-1350-4

Nathansohn, N., Schachter, J., & Gutman, H. (2005). Patterns of recurrence in patients with melanoma after radical lymph node dissection. Arch Surg, 140(12), 1172-1177. doi:10.1001/archsurg.140.12.1172

Ng, P. C., Barzilai, D. A., Ismail, S. A., Averitte, R. L., Jr., & Gilliam, A. C. (2003). Evaluating invasive cutaneous melanoma: is the initial biopsy representative of the final depth? J Am Acad Dermatol, 48(3), 420-424. doi:10.1067/mjd.2003.106

Nieweg, O. E., & Kroon, B. B. (2006). The conundrum of follow-up: should it be abandoned? Surg Oncol Clin N Am, 15(2), 319-330. doi:10.1016/j.soc.2005.12.005

NZGG. (2008). Clinical Practice Guidelines for the management of Melanoma in Australia and New Zeeland, N.Z.G Group Editor 2008. The Cancer Council Australia/Australian Cancer Network/ministry of Health, New Zeeland: Wellington.

O'Meara, A. T., Cress, R., Xing, G., Danielsen, B., & Smith, L. H. (2005). Malignant melanoma in pregnancy. A population-based evaluation. Cancer, 103(6), 1217-1226. doi:10.1002/cncr.20925

Oliveria, S. A., Hay, J. L., Geller, A. C., Heneghan, M. K., McCabe, M. S., & Halpern, A. C. (2007). Melanoma survivorship: research opportunities. J Cancer Surviv, 1(1), 87-97. doi:10.1007/s11764-007-0009-y

Olofsson Bagge, R., Mattsson, J., & Hafstrom, L. (2014). Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities--long-term follow-up of a randomised trial. Int J Hyperthermia, 30(5), 295-298. doi:10.3109/02656736.2014.931601

Omholt, K., Grafstrom, E., Kanter-Lewensohn, L., Hansson, J., & Ragnarsson-Olding, B. K. (2011). KIT pathway alterations in mucosal melanomas of the vulva and other sites. Clin Cancer Res, 17(12), 3933-3942. doi:10.1158/1078-0432.ccr-10-2917

Overgaard, J., Overgaard, M., Hansen, P. V., & von der Maase, H. (1986). Some factors of importance in the radiation treatment of malignant melanoma. Radiother Oncol, 5(3), 183-192.

Pampena, R., Kyrgidis, A., Lallas, A., Moscarella, E., Argenziano, G., & Longo, C. (2017). A meta-analysis of nevus-associated melanoma: Prevalence and practical implications. J Am Acad Dermatol, 77(5), 938-945.e934. doi:10.1016/j.jaad.2017.06.149

Patchell, R. A., Tibbs, P. A., Regine, W. F., Dempsey, R. J., Mohiuddin, M., Kryscio, R. J., . . . Young, B. (1998). Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. Jama, 280(17), 1485-1489.

Patel, B. G., Ahmed, K. A., Johnstone, P. A., Yu, H. H., & Etame, A. B. (2016). Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases. Melanoma Res, 26(4), 382-386. doi:10.1097/cmr.0000000000000250

Patel, J. K., Didolkar, M. S., Pickren, J. W., & Moore, R. H. (1978). Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg, 135(6), 807-810.

Patel, P. M., Suciu, S., Mortier, L., Kruit, W. H., Robert, C., Schadendorf, D., . . . Spatz, A. (2011). Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer, 47(10), 1476-1483. doi:10.1016/j.ejca.2011.04.030

Patuzzo, R., Maurichi, A., Camerini, T., Gallino, G., Ruggeri, R., Baffa, G., . . . Santinami, M. (2014). Accuracy and prognostic value of sentinel lymph node biopsy in head and neck melanomas. J Surg Res, 187(2), 518-524. doi:10.1016/j.jss.2013.10.037

Peccatori, F. A., Azim, H. A., Jr., Orecchia, R., Hoekstra, H. J., Pavlidis, N., Kesic, V., & Pentheroudakis, G. (2013). Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 24 Suppl 6, vi160-170. doi:10.1093/annonc/mdt199

Pelster, M. S., Gruschkus, S. K., Bassett, R., Gombos, D. S., Shephard, M., Posada, L., . . . Patel, S. P. (2020). Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study. J Clin Oncol, Jco2000605. doi:10.1200/jco.20.00605

Pereira, M. G., Baia, V., & Machado, J. C. (2016). Coping and quality of life in patients with skin tumors in the follow-up stage: The mediating role of body image and psychological morbidity. J Psychosoc Oncol, 34(5), 400-412. doi:10.1080/07347332.2016.1196807

Pereira, M. G., Ponte, M., Ferreira, G., & Machado, J. C. (2017). Quality of life in patients with skin tumors: the mediator role of body image and social support. Psychooncology, 26(6), 815-821. doi:10.1002/pon.4236

Peterson, C. (2005). Naturläkemedel - egenvård på egen risk! Fara för okända biverkningar och interaktioner med "vanliga" läkemedel. . Läkartidningen, 102.

Peuvrel, L., Ruellan, A. L., Thillays, F., Quereux, G., Brocard, A., Saint-Jean, M., . . . Dreno, B. (2013). Severe radiotherapy-induced extracutaneous toxicity under vemurafenib. Eur J Dermatol, 23(6), 879-881. doi:10.1684/ejd.2013.2193

Piris, A., Mihm, M. C., Jr., & Duncan, L. M. (2011). AJCC melanoma staging update: impact on dermatopathology practice and patient management. J Cutan Pathol, 38(5), 394-400. doi:10.1111/j.1600-0560.2011.01699.x

Piulats, J. M., Espinosa, E., de la Cruz Merino, L., Varela, M., Alonso Carrión, L., Martín-Algarra, S., . . . Berrocal-Jaime, A. (2021). Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). J Clin Oncol, Jco2000550. doi:10.1200/jco.20.00550

Pokorny, R., McPherson, J. P., Haaland, B., Grossmann, K. F., Luckett, C., Voorhies, B. N., . . . Swami, U. (2021). Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma. J Immunother Cancer, 9(1). doi:10.1136/jitc-2020-001781

Poort, H., Jacobs, J. M., Pirl, W. F., Temel, J. S., & Greer, J. A. (2019). Fatigue in patients on oral targeted or chemotherapy for cancer and associations with anxiety, depression, and quality of life. Palliat Support Care, 1-7. doi:10.1017/s147895151900066x

Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018). Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med, 378(2), 158-168. doi:10.1056/NEJMra1703481

Poulet, F. M., Wolf, J. J., Herzyk, D. J., & DeGeorge, J. J. (2016). An Evaluation of the Impact of PD-1 Pathway Blockade on Reproductive Safety of Therapeutic PD-1 Inhibitors. Birth Defects Res B Dev Reprod Toxicol, 107(2), 108-119. doi:10.1002/bdrb.21176

Prochazka, M., Granath, F., Ekbom, A., Shields, P. G., & Hall, P. (2002). Lung cancer risks in women with previous breast cancer. Eur J Cancer, 38(11), 1520-1525.

Projektet NORDCAN. Retrieved from http://www-dep.iarc.fr/NORDCAN/SW/frame.asp

Puig, S., Argenziano, G., Zalaudek, I., Ferrara, G., Palou, J., Massi, D., . . . Malvehy, J. (2007). Melanomas that failed dermoscopic detection: a combined clinicodermoscopic approach for not missing melanoma. Dermatol Surg, 33(10), 1262-1273. doi:10.1111/j.1524-4725.2007.33264.x

Qian, J. M., Yu, J. B., Kluger, H. M., & Chiang, V. L. (2016). Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer, 122(19), 3051-3058. doi:10.1002/cncr.30138

Quintas-Cardama, A., Lazar, A. J., Woodman, S. E., Kim, K., Ross, M., & Hwu, P. (2008). Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol, 5(12), 737-740. doi:10.1038/ncponc1251

Rao, R. D., Holtan, S. G., Ingle, J. N., Croghan, G. A., Kottschade, L. A., Creagan, E. T., . . . Markovic, S. N. (2006). Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer, 106(2), 375-382. doi:10.1002/cncr.21611

Rao, U. N., Ibrahim, J., Flaherty, L. E., Richards, J., & Kirkwood, J. M. (2002). Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690. J Clin Oncol, 20(8), 2053-2057.

Reddy, K. K., Farber, M. J., Bhawan, J., Geronemus, R. G., & Rogers, G. S. (2013). Atypical (dysplastic) nevi: outcomes of surgical excision and association with melanoma. JAMA Dermatol, 149(8), 928-934. doi:10.1001/jamadermatol.2013.4440

Reintgen, D. S., McCarty, K. S., Jr., Vollmer, R., Cox, E., & Seigler, H. F. (1985). Malignant melanoma and pregnancy. Cancer, 55(6), 1340-1344.

Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., . . . Daud, A. (2015). Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol, 16(8), 908-918. doi:10.1016/s1470-2045(15)00083-2

Riber-Hansen, R., Nyengaard, J. R., Hamilton-Dutoit, S. J., & Steiniche, T. (2009). Stage migration after minor changes in histologic estimation of tumor burden in sentinel lymph nodes: the protocol trap. Cancer, 115(10), 2177-2187. doi:10.1002/cncr.24268

Riber-Hansen, R., Sjoegren, P., Hamilton-Dutoit, S. J., & Steiniche, T. (2008). Extensive pathological analysis of selected melanoma sentinel lymph nodes: high metastasis detection rates at reduced workload. Ann Surg Oncol, 15(5), 1492-1501. doi:10.1245/s10434-008-9847-8

Rigel, D. S., & Carucci, J. A. (2000). Malignant melanoma: prevention, early detection, and treatment in the 21st century. CA Cancer J Clin, 50(4), 215-236; quiz 237-240.

Robbins, K. T., Clayman, G., Levine, P. A., Medina, J., Sessions, R., Shaha, A., . . . Wolf, G. T. (2002). Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery. Arch Otolaryngol Head Neck Surg, 128(7), 751-758.

Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., . . . Schadendorf, D. (2015). Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med, 372(1), 30-39. doi:10.1056/NEJMoa1412690

Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., . . . Ascierto, P. A. (2015). Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med, 372(4), 320-330. doi:10.1056/NEJMoa1412082

Robert, C., Marabelle, A., Herrscher, H., Caramella, C., Rouby, P., Fizazi, K., & Besse, B. (2020). Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm. Nat Rev Clin Oncol. doi:10.1038/s41571-020-0399-6

Robert, C., Ribas, A., Hamid, O., Daud, A., Wolchok, J. D., Joshua, A. M., . . . Hodi, F. S. (2018). Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. J Clin Oncol, 36(17), 1668-1674. doi:10.1200/jco.2017.75.6270

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., . . . Ribas, A. (2015). Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med, 372(26), 2521-2532. doi:10.1056/NEJMoa1503093

Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., . . . Wolchok, J. D. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med, 364(26), 2517-2526. doi:10.1056/NEJMoa1104621

Roberts, D. L., Anstey, A. V., Barlow, R. J., Cox, N. H., Newton Bishop, J. A., Corrie, P. G., . . . Kirkham, N. (2002). U.K. guidelines for the management of cutaneous melanoma. Br J Dermatol, 146(1), 7-17.

Robles-Espinoza, C. D., Roberts, N. D., Chen, S., & Leacy, F. P. (2016). Germline MC1R status influences somatic mutation burden in melanoma. 7, 12064. doi:10.1038/ncomms12064

Rosen, A. C., Case, E. C., Dusza, S. W., Balagula, Y., Gordon, J., West, D. P., & Lacouture, M. E. (2013). Impact of Dermatologic Adverse Events on Quality of Life in 283 Cancer Patients: A Questionnaire Study in a Dermatology Referral Clinic. American Journal of Clinical Dermatology, 14(4), 327-333. doi:10.1007/s40257-013-0021-0

Ruark. (1993). Who detects the primary reccurence in stage I cutaneous melanoma: patient or doctor? melanoma Res. 1993;3 Supplement 1:44.

Rubin, K. M., Hoffner, B., & Bullock, A. C. (2019). Caring for Patients Treated With Checkpoint Inhibitors for the Treatment of Metastatic Merkel Cell Carcinoma. Semin Oncol Nurs, 35(5), 150924. doi:10.1016/j.soncn.2019.08.003

Rychetnik, L., McCaffery, K., Morton, R., & Irwig, L. (2013). Psychosocial aspects of post-treatment follow-up for stage I/II melanoma: a systematic review of the literature. Psychooncology, 22(4), 721-736. doi:10.1002/pon.3060

Saco, M., & Mitchell, C. (2014). Severe radiation dermatitis associated with concomitant vemurafenib therapy in a patient with metastatic melanoma. J Am Acad Dermatol, 70(6), e135-136. doi:10.1016/j.jaad.2013.10.046

Sampson, J. H., Carter, J. H., Jr., Friedman, A. H., & Seigler, H. F. (1998). Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg, 88(1), 11-20. doi:10.3171/jns.1998.88.1.0011

Sause, W. T., Cooper, J. S., Rush, S., Ago, C. T., Cosmatos, D., Coughlin, C. T., . . . Lipsett, J. (1991). Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys, 20(3), 429-432.

SBU. (2014). Tidig upptäckt av symtomgivande cancer. Retrieved from http://www.sbu.se/sv/publikationer/sbu-utvarderar/Tidig-upptackt-av-symtomgivande-cancer/

Schachter, J., Ribas, A., Long, G. V., Arance, A., Grob, J. J., Mortier, L., . . . Robert, C. (2017). Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet, 390(10105), 1853-1862. doi:10.1016/s0140-6736(17)31601-x

Schank, T. E., & Hassel, J. C. (2019). Immunotherapies for the Treatment of Uveal Melanoma-History and Future. Cancers (Basel), 11(8). doi:10.3390/cancers11081048

Schwartz, J. L., Mozurkewich, E. L., & Johnson, T. M. (2003). Current management of patients with melanoma who are pregnant, want to get pregnant, or do not want to get pregnant. Cancer, 97(9), 2130-2133. doi:10.1002/cncr.11342

Scolyer, R. A., Long, G. V., & Thompson, J. F. (2011). Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. Mol Oncol, 5(2), 124-136. doi:10.1016/j.molonc.2011.03.002

Selek, U., Chang, E. L., Hassenbusch, S. J., 3rd, Shiu, A. S., Lang, F. F., Allen, P., . . . Maor, M. H. (2004). Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int J Radiat Oncol Biol Phys, 59(4), 1097-1106. doi:10.1016/j.ijrobp.2003.12.037

Shain, A. H., Yeh, I., Kovalyshyn, I., Sriharan, A., Talevich, E., Gagnon, A., . . . Bastian, B. C. (2015). The Genetic Evolution of Melanoma from Precursor Lesions. N Engl J Med, 373(20), 1926-1936. doi:10.1056/NEJMoa1502583

Sharp, L., Johansson, H., Hatschek, T., & Bergenmar, M. (2013). Smoking as an independent risk factor for severe skin reactions due to adjuvant radiotherapy for breast cancer. Breast, 22(5), 634-638. doi:10.1016/j.breast.2013.07.047

Shoushtari, A. N., Munhoz, R. R., Kuk, D., Ott, P. A., Johnson, D. B., Tsai, K. K., . . . Postow, M. A. (2016). The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer, 122(21), 3354-3362. doi:10.1002/cncr.30259

Silk, A. W., Bassetti, M. F., West, B. T., Tsien, C. I., & Lao, C. D. (2013). Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med, 2(6), 899-906. doi:10.1002/cam4.140

Slutrapport Teledermatoskopi mellan primärvårds- och hudspecialist. Retrieved from https://www.cancercentrum.se/stockholm-gotland/cancerdiagnoser/hud-och-ogon/projekt-teledermatoskopi/

Socialstyrelsen. (2019a). Statistik om cancer. Retrieved from https://www.socialstyrelsen.se/statistik-och-data/statistik/statistikamnen/cancer/

Socialstyrelsen. (2019b). Statistik om dödsorsaker. Retrieved from https://www.socialstyrelsen.se/statistik-och-data/statistik/statistikamnen/dodsorsaker/

Soderman, M., Thomsen, J. B., & Sorensen, J. A. (2016). Complications following inguinal and ilioinguinal lymphadenectomies: a meta-analysis. J Plast Surg Hand Surg, 50(6), 315-320. doi:10.3109/2000656x.2016.1173560

Sollner, W., Zschocke, I., Zingg-Schir, M., Stein, B., Rumpold, G., Fritsch, P., & Augustin, M. (1999). Interactive patterns of social support and individual coping strategies in melanoma patients and their correlations with adjustment to illness. Psychosomatics, 40(3), 239-250. doi:10.1016/s0033-3182(99)71241-7

Somach, S. C., Taira, J. W., Pitha, J. V., & Everett, M. A. (1996). Pigmented lesions in actinically damaged skin. Histopathologic comparison of biopsy and excisional specimens. Arch Dermatol, 132(11), 1297-1302.

Sondak, V. K., & Sosman, J. A. (2003). Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine. Semin Cancer Biol, 13(6), 409-415. doi:10.1016/j.semcancer.2003.09.004

Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., . . . Ribas, A. (2012). Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med, 366(8), 707-714. doi:10.1056/NEJMoa1112302

Spigel, D., McCleod, M., Hussein, M., Waterhouse, D., Einhorn, L., Horn, L., . . . Jotte, R. (2017). CheckMate153: Randomized Results of Continuous vs 1-Year Fixed-Duration Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer. Ann Oncol. 2017;28(Suppl 5): Abstract 12970

Retrieved from https://www.primeoncology.org/app/uploads/prime_activities/42584/VPS_Madrid_1297O_Lung_Spigel.pdf

Spitz, S. (1948). Melanomas of childhood. Am J Pathol, 24(3), 591-609.

Stamataki, Z., Brunton, L., Lorigan, P., Green, A. C., Newton-Bishop, J., & Molassiotis, A. (2015). Assessing the impact of diagnosis and the related supportive care needs in patients with cutaneous melanoma. Support Care Cancer, 23(3), 779-789. doi:10.1007/s00520-014-2414-x

Starritt, E. C., Joseph, D., McKinnon, J. G., Lo, S. K., de Wilt, J. H., & Thompson, J. F. (2004). Lymphedema after complete axillary node dissection for melanoma: assessment using a new, objective definition. Ann Surg, 240(5), 866-874. doi:10.1097/01.sla.0000143271.32568.2b

Stensheim, H., Moller, B., van Dijk, T., & Fossa, S. D. (2009). Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. J Clin Oncol, 27(1), 45-51. doi:10.1200/jco.2008.17.4110

Stewart, C. L., Gleisner, A., Kwak, J., Chapman, B., Pearlman, N., Gajdos, C., . . . Kounalakis, N. (2017). Implications of Sentinel Lymph Node Drainage to Multiple Basins in Head and Neck Melanoma. Ann Surg Oncol, 24(5), 1386-1391. doi:10.1245/s10434-016-5744-8

Stout, N. L., Sleight, A., Pfeiffer, D., Galantino, M. L., & deSouza, B. (2019). Promoting assessment and management of function through navigation: opportunities to bridge oncology and rehabilitation systems of care. Support Care Cancer, 27(12), 4497-4505. doi:10.1007/s00520-019-04741-0

Strouse, J. J., Fears, T. R., Tucker, M. A., & Wayne, A. S. (2005). Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database. J Clin Oncol, 23(21), 4735-4741. doi:10.1200/jco.2005.02.899

Sullivan, R. J., Atkins, M. B., Kirkwood, J. M., Agarwala, S. S., Clark, J. I., Ernstoff, M. S., . . . Kaufman, H. L. (2018). An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. J Immunother Cancer, 6(1), 44. doi:10.1186/s40425-018-0362-6

Tallet, A. V., Dhermain, F., Le Rhun, E., Noel, G., & Kirova, Y. M. (2017). Combined irradiation and targeted therapy or immune checkpoint blockade in brain metastases: toxicities and efficacy. Ann Oncol. doi:10.1093/annonc/mdx408

Tawbi, H. A., Forsyth, P. A., Algazi, A., Hamid, O., Hodi, F. S., Moschos, S. J., . . . Margolin, K. (2018). Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med, 379(8), 722-730. doi:10.1056/NEJMoa1805453

Tawbi, H. F., PA. Algazi, AP. et al. (2017). Efficacy and safety of nivolumab plus ipilimumab in patients with melanoma metastatic to the brain: Results of the phase II CheckMate 204 study. Presented June 4, 2017. Paper presented at the 2017 ASCO Annual Meeting.

Tefany, F. J., Barnetson, R. S., Halliday, G. M., McCarthy, S. W., & McCarthy, W. H. (1991). Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J Invest Dermatol, 97(2), 197-202.

Theodore, J. E., Frankel, A. J., Thomas, J. M., Barbour, A. P., Bayley, G. J., Allan, C. P., . . . Smithers, B. M. (2016). Assessment of morbidity following regional nodal dissection in the axilla and groin for metastatic melanoma. ANZ J Surg. doi:10.1111/ans.13526

Tonnesen, H., Nielsen, P. R., Lauritzen, J. B., & Moller, A. M. (2009). Smoking and alcohol intervention before surgery: evidence for best practice. Br J Anaesth, 102(3), 297-306. doi:10.1093/bja/aen401

Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016). Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer, 16(5), 275-287. doi:10.1038/nrc.2016.36

Trinh, S., Le, A., Gowani, S., & La-Beck, N. M. (2019). Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: a Minireview of Current Clinical Guidelines. Asia Pac J Oncol Nurs, 6(2), 154-160. doi:10.4103/apjon.apjon_3_19

Trumble, E. R., Smith, R. M., Pearl, G., & Wall, J. (2005). Transplacental transmission of metastatic melanoma to the posterior fossa. Case report. J Neurosurg, 103(2 Suppl), 191-193. doi:10.3171/ped.2005.103.2.0191

Tsao, M., Xu, W., & Sahgal, A. (2012). A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting with a limited number of brain metastases. Cancer, 118(9), 2486-2493. doi:10.1002/cncr.26515

Valachis, A., & Ullenhag, G. J. (2017). Discrepancy in BRAF status among patients with metastatic malignant melanoma: A meta-analysis. Eur J Cancer, 81, 106-115. doi:10.1016/j.ejca.2017.05.015

Wallach, J. B., Rietschel, P., Kalnicki, S., & Fox, J. L. (2014). BRAF inhibitor (vemurafenib) concurrent with radiation therapy for metastatic melanoma producing severe skin and oral cavity reactions. Pract Radiat Oncol, 4(5), e213-216. doi:10.1016/j.prro.2013.10.007

Walter, J. R., Xu, S., Paller, A. S., Choi, J. N., & Woodruff, T. K. (2016). Oncofertility considerations in adolescents and young adults given a diagnosis of melanoma: Fertility risk of Food and Drug Administration-approved systemic therapies. J Am Acad Dermatol, 75(3), 528-534. doi:10.1016/j.jaad.2016.04.031

van der Ploeg, A. P., van Akkooi, A. C., Schmitz, P. I., van Geel, A. N., de Wilt, J. H., Eggermont, A. M., & Verhoef, C. (2011). Therapeutic surgical management of palpable melanoma groin metastases: superficial or combined superficial and deep groin lymph node dissection. Ann Surg Oncol, 18(12), 3300-3308. doi:10.1245/s10434-011-1741-0

Weber, J., Atkins, M., Hwu, P., Radvanyi, L., Sznol, M., & Yee, C. (2011). White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clin Cancer Res, 17(7), 1664-1673. doi:10.1158/1078-0432.ccr-10-2272

Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., . . . Ascierto, P. A. (2017). Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med, 377(19), 1824-1835. doi:10.1056/NEJMoa1709030

Weber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., . . . Larkin, J. (2015). Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol, 16(4), 375-384. doi:10.1016/s1470-2045(15)70076-8

Wells, M., Macmillan, M., Raab, G., MacBride, S., Bell, N., MacKinnon, K., . . . Munro, A. (2004). Does aqueous or sucralfate cream affect the severity of erythematous radiation skin reactions? A randomised controlled trial. Radiother Oncol, 73(2), 153-162. doi:10.1016/j.radonc.2004.07.032

Verma, S., Quirt, I., McCready, D., Bak, K., Charette, M., & Iscoe, N. (2006). Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer, 106(7), 1431-1442. doi:10.1002/cncr.21760

Westerdahl, J., Olsson, H., Masback, A., Ingvar, C., Jonsson, N., Brandt, L., . . . Moller, T. (1994). Use of sunbeds or sunlamps and malignant melanoma in southern Sweden. Am J Epidemiol, 140(8), 691-699.

Wheatley. (2007). Interferon-α as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials. . Abstract presentation from the 2007 ASCO Annual Meeting retrieved from

Whiteman, D. C., Valery, P., McWhirter, W., & Green, A. C. (1997). Risk factors for childhood melanoma in Queensland, Australia. Int J Cancer, 70(1), 26-31.

Wijn, D. H., Groeneveld, G. H., Vollaard, A. M., Muller, M., Wallinga, J., Gelderblom, H., & Smit, E. F. (2018). Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events. Eur J Cancer, 104, 182-187. doi:10.1016/j.ejca.2018.09.012

Vijuk, G., & Coates, A. S. (1998). Survival of patients with visceral metastatic melanoma from an occult primary lesion: a retrospective matched cohort study. Ann Oncol, 9(4), 419-422.

Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J. J., Cowey, C. L., . . . Larkin, J. (2017). Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med, 377(14), 1345-1356. doi:10.1056/NEJMoa1709684

Wong, S. L., Balch, C. M., Hurley, P., Agarwala, S. S., Akhurst, T. J., Cochran, A., . . . Lyman, G. H. (2012). Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol, 30(23), 2912-2918. doi:10.1200/jco.2011.40.3519

Wong, S. L., Faries, M. B., Kennedy, E. B., Agarwala, S. S., Akhurst, T. J., Ariyan, C., . . . Lyman, G. H. (2017). Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. J Clin Oncol, Jco2017757724. doi:10.1200/jco.2017.75.7724

Wong, S. L., Faries, M. B., Kennedy, E. B., Agarwala, S. S., Akhurst, T. J., Ariyan, C., . . . Lyman, G. H. (2018). Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. J Clin Oncol, 36(4), 399-413. doi:10.1200/jco.2017.75.7724

Wronski, M., & Arbit, E. (2000). Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J Neurosurg, 93(1), 9-18. doi:10.3171/jns.2000.93.1.0009

Xu, W., Moor, R. J., Walpole, E. T., & Atkinson, V. G. (2019). Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature. Melanoma Res, 29(3), 333-337. doi:10.1097/cmr.0000000000000586

Yamamoto, M., Serizawa, T., Shuto, T., Akabane, A., Higuchi, Y., Kawagishi, J., . . . Tsuchiya, K. (2014). Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol, 15(4), 387-395. doi:10.1016/s1470-2045(14)70061-0

Yao, K. A., Hsueh, E. C., Essner, R., Foshag, L. J., Wanek, L. A., & Morton, D. L. (2003). Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma? Ann Surg, 238(5), 743-747. doi:10.1097/01.sla.0000094440.50547.1d

Youl, P., Aitken, J., Hayward, N., Hogg, D., Liu, L., Lassam, N., . . . Green, A. (2002). Melanoma in adolescents: a case-control study of risk factors in Queensland, Australia. Int J Cancer, 98(1), 92-98.

Yu, J. B., & Chiang, V. L. (2016). Reply to timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer. doi:10.1002/cncr.30243

Ziegler, J. C., & Cooper, J. S. (1986). Brain metastases from malignant melanoma: conventional vs. high-dose-per-fraction radiotherapy. Int J Radiat Oncol Biol Phys, 12(10), 1839-1842.

Zimmer, L., Livingstone, E., Hassel, J. C., Fluck, M., Eigentler, T., Loquai, C., . . . Schadendorf, D. (2020). Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, 395(10236), 1558-1568. doi:10.1016/s0140-6736(20)30417-7

Nästa kapitel
21 Vårdprogramgruppen